Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia

Launched by THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY · Aug 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the occurrence of systemic mastocytosis in patients who have a specific type of acute myeloid leukemia (AML) known as t(8;21) AML. The researchers want to find out how common systemic mastocytosis is in these patients and how well they respond to their initial treatment. This is important because it can help doctors understand the overall health outlook for patients receiving standard therapy for this type of leukemia.

To participate in this study, individuals must be at least 5 years old and newly diagnosed with t(8;21) AML, meaning they have not received treatment yet. They also need to be able to understand the study and agree to take part by signing a consent form. However, patients who already have a diagnosis of systemic mastocytosis or have certain substance abuse issues will not be eligible. If you join the study, you can expect to be monitored closely to help gather information that can improve treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Male or female, Age (years) \>= 5;
• • 2. Newly diagnosed as t(8;21) AML patients according to World Health Organization (WHO) classification;
• • 3. Patients who sign the informed consent must have the ability to understand and be willing to participate in the study and sign the informed consent.
• Exclusion Criteria:
• • 1. The t(8;21) AML patients with SM have been diagnosed already;
• • 2. Patients with drug abuse or long-term alcoholism that affected the evaluation of trial results;
• • 3. Patients were deemed unsuitable for enrolment by the investigator.